Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01140841 · ClinicalTrials.gov registry record
A Study of Safety and Tolerability of Fipamezole in Adult Subjects With Parkinson's Disease Who Are Receiving Levodopa
A clinical trial, sponsored by Bausch Health Americas.
- Completed
- Registry status
- 40
- Enrollment target
NCT01140841: Completed study, sponsored by Bausch Health Americas.
NCT01140841 is a clinical trial that has completed, run by Bausch Health Americas. The registered enrollment target is 40 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01140841 has completed, sponsored by Bausch Health Americas.
- COMPLETED
- Registry status
- 40 participants
- Enrollment target
Study Summary
The purpose of this clinical trial is to determine the maximum tolerated dose of Fipamezole in adult patients with Parkinson's disease who are receiving levodopa.
Interventions
- DRUG Placebo
- DRUG Fipamezole ODT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2010-06 |
| Est. Completion | 2010-11 |
What the finished NCT01140841 record still lists
NCT01140841 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 40 participants, a relatively small participant target.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01140841 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01140841 about?
NCT01140841 is a clinical study titled "A Study of Safety and Tolerability of Fipamezole in Adult Subjects With Parkinson's Disease Who Are Receiving Levodopa". The purpose of this clinical trial is to determine the maximum tolerated dose of Fipamezole in adult patients with Parkinson's disease who are receiving levodopa.
What is the current status of trial NCT01140841?
This trial is currently completed. The enrollment target is 40 participants. The study started on 2010-06. Estimated completion is 2010-11.
What interventions are being tested in trial NCT01140841?
The interventions under investigation include: Placebo (DRUG), Fipamezole ODT (DRUG).
Who is sponsoring clinical trial NCT01140841?
This trial is sponsored by Bausch Health Americas, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia